Polymyxin B Sulfate And Trimethoprim Solution
NDC Package 61314-628-10
Package Information
Polymyxin B Sulfate And Trimethoprim solution is polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenzae and Pseudomonas aeruginosa.**Efficacy for this organism in this organ system was studied in fewer than 10 infections. This formulation utilizes a solution delivery system. Marketed by Sandoz Inc, this product is identified by NDC 61314-628 and is authorized under FDA application ANDA064211.
Identification & Billing
- RxCUI: 244967 - polymyxin B sulfate 10,000 UNT / trimethoprim sulfate 1 MG in ML Ophthalmic Solution
- RxCUI: 244967 - polymyxin B 10000 UNT/ML / trimethoprim 1 MG/ML Ophthalmic Solution
- RxCUI: 244967 - polymyxin B 10,000 UNT / trimethoprim (as trimethoprim sulfate) 0.1 % Ophthalmic Solution
- RxCUI: 244967 - polymyxin B 10,000 UNT / trimethoprim 0.1 % Ophthalmic Solution
- RxCUI: 244967 - Polymyxin B 10000 UNT/ML / TMP 1 MG/ML Ophthalmic Solution
Clinical Specifications
- Cytochrome P450 2C8 Inhibitors - [MoA] (Mechanism of Action)
- Dihydrofolate Reductase Inhibitor Antibacterial - [EPC] (Established Pharmacologic Class)
- Dihydrofolate Reductase Inhibitors - [MoA] (Mechanism of Action)
- Organic Cation Transporter 2 Inhibitors - [MoA] (Mechanism of Action)
- Polymyxin-class Antibacterial - [EPC] (Established Pharmacologic Class)
- Polymyxins - [CS]
Regulatory & Marketing
Hierarchy Structure
- 61314 - Sandoz Inc
- 61314-628 - Polymyxin B Sulfate And Trimethoprim
- 61314-628-10 - 1 BOTTLE, PLASTIC in 1 CARTON / 10 mL in 1 BOTTLE, PLASTIC
- 61314-628 - Polymyxin B Sulfate And Trimethoprim
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 61314-628-10 identifies a specific commercial package of 1 bottle, plastic in 1 carton / 10 ml in 1 bottle, plastic of Polymyxin B Sulfate And Trimethoprim, a human prescription drug labeled by Sandoz Inc. This solution is formulated for ophthalmic use and contains polymyxin b sulfate; trimethoprim sulfate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sandoz Inc on April 16, 1998. The current certification is valid through December 31, 2027.
How is this Sandoz Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 61314062810. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.